Biomarker & Intervention Discovery
ADHD
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
NIH funding$73MFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionSpontaneous remission by adulthood: 30-70% symptom reduction (depending on definition); functionally impairing ADHD…
Best-intervention remissionStimulant medications (methylphenidate, amphetamines): 60-80% response rate; MTA study: combined medication +…
Gap sizeModerate — substantial underdiagnosis especially in girls/women and adults; treatment gaps exist but pharmacotherapy…
Primary barrieraccess/framing
Full remission profile →
Remission & chronicity
Spontaneous remission
Spontaneous remission by adulthood: 30-70% symptom reduction (depending on definition); functionally impairing ADHD persists into adulthood in 50-65% of childhood cases; DSMIV criteria met in adulthood in ~50%
Best-intervention remission
Stimulant medications (methylphenidate, amphetamines): 60-80% response rate; MTA study: combined medication + behavioural treatment superior to either alone; behavioural interventions alone: 30-50% symptom reduction in children; non-stimulant (atomoxetine, viloxazine): 40-60% response
Gap size
Moderate — substantial underdiagnosis especially in girls/women and adults; treatment gaps exist but pharmacotherapy is highly effective when accessed
Primary barrier
access/framing
Stimulant shortages (2022-present in US) have left many patients without medication; adult ADHD massively underdiagnosed for decades; medication diversion concerns create barriers to legitimate access; non-pharmacological approaches (CBT, exercise, dietary interventions) chronically under-supported
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “ADHD” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."